Can I Take Rhodiola with Praluent (Alirocumab)?

How Alirocumab Works, and Why CYP Enzymes Are Not the Issue

Alirocumab is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9) in plasma, preventing it from degrading LDL receptors on hepatocytes. More LDL receptors on the liver surface means more LDL-C is pulled out of circulation.

Because it is a large protein molecule, alirocumab does not pass through the liver's CYP450 enzyme system the way small-molecule drugs do. The FDA label for Praluent states that the drug "is not expected to be a substrate, inhibitor, or inducer of CYP enzymes or drug transporters." [1] Clearance occurs through two parallel paths: a saturable, target-mediated route (binding to PCSK9 itself) and a non-saturable proteolytic degradation route, identical to the way the body breaks down any IgG antibody. [1]

What This Means for Supplement Interactions

Because CYP enzymes are not involved, any supplement that inhibits or induces CYP3A4, CYP2C9, or other isoforms, including many herbal products, cannot meaningfully alter alirocumab blood levels. This is fundamentally different from statins such as simvastatin or atorvastatin, which are CYP3A4 substrates and therefore vulnerable to a wide range of herb-drug interactions. [2]

The interaction concern with rhodiola, then, is not about changing how much alirocumab is in your blood. It is about what rhodiola itself does once it is in the body alongside your full medication list.

The ODYSSEY OUTCOMES Trial Context

The ODYSSEY OUTCOMES trial (N=18,924 patients with recent acute coronary syndrome) showed alirocumab 75-150 mg reduced major adverse cardiovascular events by 15% versus placebo (HR 0.85, 95% CI 0.78-0.93, P<0.001) and reduced all-cause mortality by 15% (HR 0.85, 95% CI 0.73-0.98). [3] Patients in that trial were on maximal statin therapy. Supplement use was not systematically recorded, which is a common gap in large cardiovascular trials. [3]

What Rhodiola Rosea Actually Does Pharmacologically

Rhodiola rosea is a flowering plant native to arctic and mountainous regions of Europe and Asia. It has been used in traditional medicine for centuries as an adaptogen, a substance claimed to help the body resist physical and mental stress.

The primary bioactive compounds are rosavins and salidroside. These constituents have measurable effects on neurotransmitter systems, which is exactly where the safety questions arise.

Serotonergic Activity

Salidroside has been shown in animal models to inhibit monoamine oxidase A (MAO-A) and MAO-B. [4] MAO-A breaks down serotonin, dopamine, and norepinephrine. Inhibiting it, even weakly, can increase synaptic levels of those neurotransmitters. A 2015 review in Phytomedicine documented preclinical evidence for rhodiola's serotonin reuptake inhibition and MAO inhibition, placing it in a pharmacological category shared by antidepressants. [4]

This is clinically relevant when a patient on alirocumab is also taking:

• Any selective serotonin reuptake inhibitor (SSRI such as sertraline or escitalopram)
• Any serotonin-norepinephrine reuptake inhibitor (SNRI such as duloxetine or venlafaxine)
• Tricyclic antidepressants
• Tramadol or other opioids with serotonergic properties
• Buspirone or lithium

In that context, adding rhodiola could theoretically increase serotonin burden, raising the risk of serotonin syndrome. Serotonin syndrome ranges from mild (tremor, diarrhea, mild agitation) to life-threatening (hyperthermia above 41.1 °C, muscle rigidity, rhabdomyolysis). [5]

Effects on Blood Pressure and Heart Rate

Several small trials in humans have examined rhodiola's cardiovascular signals. A 2012 placebo-controlled trial (N=60) published in Planta Medica found no significant change in resting heart rate or blood pressure after 4 weeks of standardized Rhodiola rosea extract (SHR-5, 170 mg/day). [6] A separate pilot study in patients with stress-related burnout syndrome showed modest reductions in cortisol levels but no clinically significant hemodynamic changes. [7]

For someone taking alirocumab for established ASCVD, marginal blood pressure effects from an adaptogen are worth tracking, but they do not represent a contraindication. The more relevant concern remains the serotonergic pathway, not direct cardiac hemodynamics.

Platelet Aggregation Signal

Salidroside and other rhodiola constituents have shown antiplatelet activity in in-vitro studies. [8] If a patient on alirocumab is also on aspirin, clopidogrel, or anticoagulants (common in the ASCVD population), adding an antiplatelet herb introduces additive bleeding risk. This is an indirect interaction, rhodiola is not interacting with alirocumab but with the rest of the cardiovascular drug regimen that frequently accompanies Praluent use.

Pharmacokinetic Profile of Rhodiola and CYP Enzyme Effects

Rhodiola's bioactive compounds are metabolized primarily through hepatic and intestinal CYP enzymes. Salidroside undergoes phase II glucuronidation. The rosavins interact with CYP3A4 and CYP2C9 in in-vitro assays, though at concentrations that may exceed those achieved with typical supplement doses. [9]

Does Rhodiola Inhibit CYP Enzymes?

In-vitro data suggest moderate CYP3A4 inhibitory potential for some rhodiola extracts. [9] If that effect were clinically significant, it would matter for a patient taking a statin alongside alirocumab, but it would not alter alirocumab levels for the reason already stated: alirocumab bypasses CYP450 entirely.

The caveat is that the patient's full drug list matters. Someone on alirocumab plus simvastatin plus a CYP3A4-metabolized antidepressant could theoretically see drug level changes from rhodiola's CYP effects on those other agents, while alirocumab itself sits unaffected.

Bioavailability and Dose Variability in Supplements

Commercial rhodiola products are not standardized uniformly. Salidroside content ranges from 0.8% to 3% and rosavin content from 3% to 5% in products labeled "standardized." A 2018 ConsumerLab analysis of 27 rhodiola products found that 3 of 27 contained less than 80% of the labeled salidroside dose. [10] This variability complicates risk prediction, a product with unexpectedly high active-compound content could push CYP inhibition into a clinically relevant range.

Direct Interaction Assessment: Alirocumab and Rhodiola Head-to-Head

No published randomized controlled trial, case report, or pharmacokinetic study has examined the combination of alirocumab and rhodiola rosea directly. The interaction assessment below is therefore built from mechanism-based reasoning and indirect evidence.

The HealthRX clinical team uses a four-axis framework when evaluating PCSK9 inhibitor plus adaptogen combinations:

Axis 1, Pharmacokinetic interference with the biologic itself. For alirocumab: low risk. Monoclonal antibodies are not CYP substrates.

Axis 2, Pharmacodynamic interaction with alirocumab's target effect (LDL-C lowering). No evidence that rhodiola constituents upregulate PCSK9, downregulate LDL receptors, or otherwise counteract the drug's lipid-lowering effect. Rodent data actually suggest salidroside may have mild lipid-modulating properties, but human RCT evidence is insufficient to quantify this. [11]

Axis 3, Pharmacodynamic interaction with co-prescribed drugs in the typical ASCVD regimen. Moderate concern. Many patients on alirocumab also take statins, antiplatelets, antihypertensives, and sometimes antidepressants. Rhodiola's serotonergic, antiplatelet, and CYP3A4 inhibitory signals could interact with those agents.

Axis 4, Patient-specific amplifiers. Higher risk in patients on SSRIs or SNRIs, those with a history of serotonin syndrome, patients on dual antiplatelet therapy, and patients with hepatic impairment (which slows rhodiola metabolism).

Summary Rating

Using this axis scoring: the alirocumab-rhodiola pairing itself is rated low direct interaction risk. The combination across a typical ASCVD drug regimen is rated moderate contextual risk, largely driven by axis 3.

Clinical Monitoring if You Are Already Taking Both

If a patient is already using rhodiola and starts alirocumab, or vice versa, there is no established requirement to stop one or the other based on current evidence. The approach is disclosure and monitoring.

What to Monitor

Your prescriber should know your rhodiola dose and brand. At a minimum, track:

• LDL-C at the standard 4-8 week post-initiation check (alirocumab's label recommends measuring lipids within 4-8 weeks of starting or dose-adjusting). [1] If LDL-C is not reaching target, consider whether the supplement could be interacting with co-prescribed statins rather than with alirocumab itself.
• Blood pressure and heart rate at routine cardiology or primary care visits. Rhodiola's hemodynamic effects are small, but an ASCVD patient's cardiovascular targets are tighter than average.
• Symptoms of serotonin excess if you are on any serotonin-active medication alongside both. Early symptoms include restlessness, rapid heart rate, dilated pupils, and muscle twitching. [5]
• Bleeding tendency if on aspirin or other antiplatelets. Easy bruising or prolonged wound bleeding warrants a call to your prescriber.

Dose-Separation Windows

Unlike some drug-supplement combinations, there is no evidence that separating the timing of rhodiola ingestion from alirocumab injection reduces interaction risk. Alirocumab is injected subcutaneously and absorbs over days; rhodiola's oral pharmacokinetics peak at 1-2 hours and clear within 24 hours. Because the interaction is pharmacodynamic rather than absorption-based, time separation does not provide meaningful protection.

When to Stop Rhodiola

Discontinue rhodiola and contact your prescriber promptly if you develop any of the following:

• Agitation, confusion, or rapid heartbeat appearing after adding rhodiola to an existing serotonin-active regimen
• Unusual bleeding (gums, skin, prolonged post-cut oozing) beyond what was present before adding the supplement
• Any unexplained muscle pain or weakness (to rule out statin myopathy aggravated by CYP3A4 inhibition if you are on a CYP3A4-metabolized statin)

What the Evidence Looks Like for Rhodiola in Cardiovascular Patients

There are no dedicated trials of rhodiola in patients with familial hypercholesterolemia or established ASCVD. Most human evidence comes from stress and fatigue populations.

A 2020 systematic review in Current Cardiology Reviews identified rhodiola's cardioprotective signals in preclinical models, including reduced ischemia-reperfusion injury and anti-arrhythmic effects, but concluded that "human clinical data remain insufficient to support cardiovascular-specific therapeutic claims." [12]

A Cochrane-style systematic review published in 2018 in Phytomedicine (covering 11 RCTs, N=1,190 total participants) found rhodiola to be generally well tolerated, with dizziness and dry mouth as the most common adverse events, and no serious cardiac adverse events reported in any included trial. [13] None of those 11 trials included patients on PCSK9 inhibitors.

The American Heart Association does not currently have a position statement on rhodiola specifically. The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease notes broadly that "dietary supplements are not recommended for cardiovascular disease prevention" due to insufficient evidence. [14]

Regulatory and Labeling Considerations

The FDA does not require supplement manufacturers to prove safety or efficacy before sale. Rhodiola is sold as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA), meaning it bypasses the drug approval pathway that generated alirocumab's safety database. [15]

Praluent's FDA-approved prescribing information does not list any herbal supplement interactions by name. The interaction section states that no clinical drug interaction studies have been conducted, which is standard for monoclonal antibodies because their lack of CYP metabolism makes traditional drug interaction studies less necessary. [1]

This regulatory gap means that the absence of a listed interaction is not evidence that no interaction exists, it is evidence that the combination has not been formally studied.

Practical Guidance for Patients and Clinicians

Patients already stable on alirocumab who want to start rhodiola should take the following steps.

First, disclose the intention to the prescribing cardiologist or lipidologist before purchasing the supplement. Bring the specific product label so the provider can check standardization levels.

Second, review the complete medication list for serotonergic agents and antiplatelet drugs. If either is present, the risk-benefit discussion needs to include those co-medications explicitly.

Third, if the prescriber approves, start at the lowest labeled dose of rhodiola (typically 50-100 mg standardized extract once daily) rather than jumping to the higher end of typical commercial dosing (200-600 mg/day).

Fourth, schedule a lipid panel 6-8 weeks after adding the supplement, which aligns with the routine alirocumab monitoring window anyway. [1] This check verifies that LDL-C response remains on target.

The Natural Medicines database (formerly Natural Medicines Comprehensive Database) rates the alirocumab-rhodiola interaction as having insufficient evidence for a definitive rating, placing it in the "minor or unknown" interaction category based on the indirect pharmacodynamic signals described above. [16]

For clinicians, the 2021 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction recommends verifying "all prescription, over-the-counter, and supplement use" before and during PCSK9 inhibitor therapy, specifically because the typical ASCVD patient carries polypharmacy risk. [17]